Introduction: OnabotulinumtoxinA (BT-A) quarterly was the first treatment approved specifically for chronic migraine (CM). It is unclear whether three cycles are better than two to assess early BT-A response. Methods: We performed a retrospective analysis on real-life prospectively collected data in 16 European headache centers. All the centers provided data on patients treated with BT-A for CM over the first three cycles of treatment. For each treatment cycle we defined patients as “good responders” if reporting a ≥ 50% reduction in monthly headache days compared with the three months before starting BT-A, “partial responders” if reporting a 30–49% reduction in monthly headache days, and “non-responders” if reporting a < 30% reduction i...
Altres ajuts: The literature search was funded by a grant from the European Headache Federation.Onab...
OnabotulinumtoxinA is one of the main preventive treatments for chronic migraine. Despite that up to...
The identification of patients who can benefit the most from the available preventive treatments is ...
OnabotulinumtoxinA (BT-A) quarterly was the first treatment approved specifically for chronic migrai...
IntroductionOnabotulinum toxin A (OnabotA) cyclic treatment is approved for the prophylactic treatme...
BACKGROUND: Chronic migraine is a complex clinical condition often undertreated. Onabotulinumtoxin ...
Introduction: Management of chronic migraine is challenging. OnabotulinumtoxinA (OBT-A) is the only ...
The identification of patients who can benefit the most from the available preventive treatments is ...
Objective: To clarify whether the clinical response after the first 2 cycles with Onabotulinumtoxin ...
Abstract Background OnabotulinumtoxinA is approved for the prevention of headache in those with chro...
Objective: To evaluate the early response of onabotulinumtoxinA as a treatment tool in patients with...
BACKGROUND: Migraine is a debilitating neurological disorder that affects 14.1% of the US and 14.7% ...
Introduction: WHO ranks migraine as the 6th highest cause of disability worldwide when considered al...
Introduction: OnabotulinumtoxinA (BT-A) is a preventive treatment for chronic migraine (CM), which n...
Altres ajuts: The literature search was funded by a grant from the European Headache Federation.Onab...
OnabotulinumtoxinA is one of the main preventive treatments for chronic migraine. Despite that up to...
The identification of patients who can benefit the most from the available preventive treatments is ...
OnabotulinumtoxinA (BT-A) quarterly was the first treatment approved specifically for chronic migrai...
IntroductionOnabotulinum toxin A (OnabotA) cyclic treatment is approved for the prophylactic treatme...
BACKGROUND: Chronic migraine is a complex clinical condition often undertreated. Onabotulinumtoxin ...
Introduction: Management of chronic migraine is challenging. OnabotulinumtoxinA (OBT-A) is the only ...
The identification of patients who can benefit the most from the available preventive treatments is ...
Objective: To clarify whether the clinical response after the first 2 cycles with Onabotulinumtoxin ...
Abstract Background OnabotulinumtoxinA is approved for the prevention of headache in those with chro...
Objective: To evaluate the early response of onabotulinumtoxinA as a treatment tool in patients with...
BACKGROUND: Migraine is a debilitating neurological disorder that affects 14.1% of the US and 14.7% ...
Introduction: WHO ranks migraine as the 6th highest cause of disability worldwide when considered al...
Introduction: OnabotulinumtoxinA (BT-A) is a preventive treatment for chronic migraine (CM), which n...
Altres ajuts: The literature search was funded by a grant from the European Headache Federation.Onab...
OnabotulinumtoxinA is one of the main preventive treatments for chronic migraine. Despite that up to...
The identification of patients who can benefit the most from the available preventive treatments is ...